International Stem Cell Corp (ISCO) financial statements (2021 and earlier)

Company profile

Business Address 5950 PRIESTLY DRIVE
CARLSBAD, CA 92008
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1010011
Cash and cash equivalents1010011
Receivables0210110
Inventory, net of allowances, customer advances and progress billings1121112
Inventory1121112
Deferred tax assets   00
Other undisclosed current assets0011000
Total current assets:2343234
Noncurrent Assets
Inventory, Noncurrent001110 
Operating lease, right-of-use asset11
Property, plant and equipment1100001
Intangible assets, net (including goodwill)1133333
Intangible assets, net (excluding goodwill)1133333
Other undisclosed noncurrent assets0000000
Total noncurrent assets:3344544
TOTAL ASSETS:5787777
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1111122
Accounts payable0101111
Accrued liabilities0111012
Debt 0     
Due to related parties  2  30
Other undisclosed current liabilities1023204
Total current liabilities:1255467
Noncurrent Liabilities
Long-term debt and lease obligation11     
Operating lease, liability11
Liabilities, other than long-term debt220   0
Deferred rent credit  0
Deferred tax liabilities, net    0
Due to related parties22     
Other undisclosed noncurrent liabilities10     
Total noncurrent liabilities:430   0
Total liabilities:5555467
Stockholders' equity
Stockholders' equity attributable to parent, including:(4)(3)32320
Common stock0000000
Additional paid in capital1051031091071029995
Accumulated deficit(109)(106)(107)(105)(98)(97)(95)
Other undisclosed stockholders' equity attributable to parent0000000
Other undisclosed stockholders' equity44     
Total stockholders' equity:(0)132320
Other undisclosed liabilities and equity      (0)
TOTAL LIABILITIES AND EQUITY:5787777

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues79117787
Revenue, net7787
Cost of revenue(3)(4)(4)(2)(2)(2)(2)
Financial services costs (1) (1)
Gross profit:4675555
Operating expenses(7)(11)(10)(10)(10)(10)(14)
Other undisclosed operating income      0
Operating loss:(3)(6)(3)(5)(5)(5)(9)
Nonoperating income (expense)011(1)42(4)
Interest and debt expense(0)(0)(0)(0)(0)(0)(0)
Loss from continuing operations before equity method investments, income taxes:(3)(4)(2)(6)(1)(3)(12)
Other undisclosed income from continuing operations before income taxes  00000
Loss before gain (loss) on sale of properties:(3)(4)(2)(6)(1)(3)(12)
Other undisclosed net income00     
Net loss available to common stockholders, diluted:(3)(4)(2)(6)(1)(3)(12)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(3)(4)(2)(6)(1)(3)(12)
Comprehensive loss, net of tax, attributable to parent:(3)(4)(2)(6)(1)(3)(12)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: